LungCancer Panel v1.0 is specifically designed for lung cancer research. This panel involves 24 genes, including full coding regions from 19 genes and non-exonic regions with frequent fusion occurrence in lung cancer.
Genes with coding regions covered
ALK |
BRAF |
CD274 |
CD74 |
EGFR |
ERBB2 |
EZR |
FGFR1 |
FGFR2 |
FGFR3 |
KRAS |
MET |
NRAS |
NTRK1 |
NTRK2 |
NTRK3 |
NUTM1 |
PDCD1LG2 |
PDGFRA |
PIK3CA |
RET |
ROS1 |
SDC4 |
SLC34A2 |
Table 1. Performance of LungCancer Panel v1.0
Platform |
On-target rate (%) |
Duplication (%) |
% target
> 0.2 x mean |
% target
> 0.5 x mean |
% target
> 1 x mean |
Fold 80 base penalty |
MGI |
92.75 |
6.20 |
99.21 |
96.21 |
52.12 |
1.28 |
Illumina®️ |
93.98 |
12.21 |
99.98 |
97.92 |
52.14 |
1.27 |
Fig 1. Evaluation of LungCancer Panel v1.0 on the analysis of SNVs and indels. The DNA libraries were prepared from Onco SNV Multiplex 1-25% gDNA (GeneWell, GW-OGTM004) using NadPrep library kits. The enriched libraries were sequenced either on HiSeq X Ten (PE150) or DNBSEQ-G400 (PE100).
Catalog# |
Color Of Tube Cap |
Item |
Volume |
Package/Storage |
1001922 |
|
LungCancer Panel v1.0, 16 rxn |
70 μl×1 |
–20℃ |
1001921 |
|
LungCancer Panel v1.0, 96 rxn |
415 μl×1 |
–20℃ |
No. This kit is
compatible only with gDNA or cDNA as initial samples. For RNA samples, reverse
transcription to generate cDNA is required prior to library preparation.
This kit supports
50-2,000 ng of gDNA or cDNA. For input amount exceeds 2,000 ng, split the
sample into multiple reactions to maintain amplification efficiency.
The main peak of
PCR products by using this kit is ~270 bp. PE150 sequencing is recommended for
high-quality coverage.
A minimum of 0.3
Gb is recommended to detect clones at 0.01% abundance with an input of 200 ng.
Increase data volume to enhance sensitivity for low-frequency clones.
Yes. This kit
includes IG Primer Mix and TR Primer Mix with gene-specific primers provided in
separate tubes, allowing flexible combination in a single amplification
reaction. With its high sensitivity, the kit meets the requirements for MRD
monitoring technology development and clinical applications, making it ideal
for low-frequency variant detection scenarios.
Product |
Catalog# |
LungCancer Panel v1.0, 16 rxn |
1001922 |
LungCancer Panel v1.0, 96 rxn |
1001921 |
Nanodigmbio will contact you within 1 day.
If there are any problems, please contact us by 400 8717 699 / support@njnad.com